PHARMACOKINETICS (PK) OF FENOFIBRIC ACID AND ROSUVASTATIN IN SUBJECTS WITH MILD TO MODERATE RENAL IMPAIRMENT.

被引：0
|
作者：
Zhu, T. [1 ]
Williams, L. [1 ]
Awni, W. [1 ]
Smith, W. [2 ]
Locke, C. [1 ]
Pradhan, R. [1 ]
机构：
[1] Abbott Labs, Abbott Pk, IL 60064 USA
[2] New Orleans Ctr Clin Res, Knoxville, TN USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 87卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [31] Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment.
    Ravis, WR
    Stokes, TJ
    Reid, S
    Van Ess, PJ
    Roniker, B
    Sica, D
    Tolbert, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P37 - P37
  • [32] Xemilofiban (XEM) single and multiple dose PK and PD in subjects with and without renal impairment.
    Sica, D
    Gehr, T
    Ruddley, J
    Fakhry, I
    Karim, A
    Anders, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 236 - 236
  • [33] Neuropathologic features in subjects with mild cognitive impairment.
    Parisi, JE
    Dickson, DW
    Johnson, KA
    Ivnik, RJ
    Smith, GE
    Tangalos, EG
    Boeve, BF
    Kokmen, E
    Petersen, RC
    BRAIN PATHOLOGY, 2000, 10 (04) : 620 - 620
  • [34] Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment
    S. G. Simonson
    P. D. Martin
    P. Mitchell
    D. W. Schneck
    K. C. Lasseter
    M. J. Warwick
    European Journal of Clinical Pharmacology, 2003, 58 : 669 - 675
  • [35] Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment
    O'Connor-Semmes, Robin
    Walker, Susan
    Kapur, Anita
    Hussey, Elizabeth K.
    Ye, June
    Wang-Smith, Laurene
    Tao, Wenli
    Dobbins, Robert L.
    Cheatham, Bentley
    Wilkison, William O.
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (07) : 1077 - 1083
  • [36] PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment
    Hoshide, S
    Takahashi, Y
    Ishikawa, T
    Kubo, J
    Tsuchimoto, M
    Komoriya, K
    Ohno, I
    Hosoya, T
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9): : 1117 - 1118
  • [37] Pharmacokinetics, Safety, and Tolerability of Tanimilast Following Single Administration in Subjects With Mild, Moderate, and Severe Renal Impairment
    Emirova, A.
    Piccino, A.
    Balzano, D.
    Rizzo, E.
    Bellatti, P.
    Rostello, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [38] Pharmacokinetics of eslicarbazepine acetate in patients with moderate liver impairment.
    Maia, Joana
    Potgieter, J. Henk
    Almeida, Luis
    Soares-da-Silva, P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09): : 1192 - 1192
  • [39] Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment
    Simonson, SG
    Martin, PD
    Mitchell, P
    Schneck, DW
    Lasseter, KC
    Warwick, MJ
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 58 (10) : 669 - 675
  • [40] Pharmacokinetics and tolerability of bosentan in patients with mild liver impairment.
    van Giersbergen, P
    Popescu, G
    Dingamanse, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P84 - P84
12345